Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

Study Overview
=================
Brief Summary
-----------------
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.

Detailed Description
-----------------
Patient to be registered at the Haematology-Oncology department Mount Sinai Roosevelt Hospital. Inclusion criteria are as follows: All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of thrombocytopenia Confirmed aplastic anemia [as assessed through bone marrow trephine biopsy]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.

Official Title
-----------------
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

Conditions
-----------------
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia

Intervention / Treatment
-----------------
* Other: Immune Thrombocytopenics
* Other: Hypo-proliferative thrombocytopenics
* Other: Control Population


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by response to intravenous immune globulin (IVIG), glucocorticoids, or winRho and exclusion of all other possible causes of thrombocytopenia Confirmed aplastic anemia [as assessed through bone marrow trephine biopsy] Chemotherapy induced thrombocytopenia assessed at time of predicted nadir. Exclusion Criteria: Suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism Chronic active hepatitis Those infected with HIV Patients receiving concomitant radiotherapy Gravid females Congenital thrombocytopenias

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Immune Thrombocytopenics<br>The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population. | Other: Immune Thrombocytopenics<br>* Full blood count with extended platelet parameters<br>* Other names: MPM (pg);|
| Hypo-proliferative thrombocytopenics<br>The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia], and a control population. | Other: Hypo-proliferative thrombocytopenics<br>* Full blood count with extended platelet parameters<br>* Other names: MPM (pg);|
| Control Pupulation<br>comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM | Other: Control Population<br>* Full blood count with extended platelet parameters<br>* Other names: MPM (pg);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increased platelet density |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mean platelet mass |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ITP, Thrombocytopenia, mean platelet mass, mean platelet component